




































CLAIMS:











1. An oral dosage form, comprising a compound selected from:











	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	
	










	
	
	
	
	









	
	
	
	
	











	
	
	
	
	









	
	
	
	
	









	
	
	
	
	









	
	
	
	
	











	
	
	
	











	
	
	
	
	









	
	
	
	











	
	
	
	











	
	
	
	











	
	
	
	
	











	
	
	
	
	










	
	
	
	













	
	
	
	
	













	
	
	
	
	











	
	
	
	
	











	
	
	
	
	













	
	
	
	
	











	
	
	
	
	
	











	
	
	
	
	
	









	
	
	
	
	











	
	
	
	
	











	
	
	
	
	
	









	
	
	
	
	











	
	
	
	
	











	
	
	
	











	
	
	
	
	









	
	
	
	
	









	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	
	









	
	
	
	









	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	











	
	
	
	









	
	
	
	
	









	
	
	
	
	











	
	
	
	
	











	
	
	
	
	




	
	
	
	
	

, or a pharmaceutically acceptable salt or prodrug thereof; and

a pharmaceutically acceptable carrier;



wherein the oral dosage form comprises about 10 mg to about 500 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.











2. The oral dosage form of claim 1, comprising about 10 mg to about 250 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.











3. The oral dosage form of claim 1, wherein the oral dosage form is a capsule.











4. The oral dosage form of claim 3, wherein the capsule is a hard or soft gelatin capsule.











5. Use of a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for inhibiting ALK2 kinase, wherein the medicament is for oral administration, and the compound is selected from:











	











	
	
	
	
	











	
	
	
	
	









	
	
	
	
	











	
	
	
	
	










	
	
	
	
	









	
	
	
	
	











	
	
	
	
	











	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	









	
	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	
	













	
	
	
	













	
	
	
	
	













	
	
	
	
	











	
	
	
	
	











	
	
	
	
	













	
	
	
	
	
	











	
	
	
	
	
	











	
	
	
	
	
	









	
	
	
	
	











	
	
	
	
	











	
	
	
	
	
	









	
	
	
	
	











	
	
	
	
	











	
	
	
	











	
	
	
	
	









	
	
	
	
	









	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	
	









	
	
	
	









	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	











	
	
	
	









	
	
	
	
	









	
	
	
	
	











	
	
	
	
	











	
	
	
	
	




	
	
	
	
	

; and



wherein the therapeutically effective amount is about 10 to about 500 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.











6. The use of claim 5, wherein the ALK2 kinase comprises a mutation.











7. The use of claim 6, wherein the mutation is an activating mutation.











8. The use of claim 7, wherein the activating mutation is R206H.











9. Use of a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for treating fibrodysplasia ossificans progressiva, wherein the medicament is for oral administration, and the compound is selected from:











	











	
	
	
	
	











	
	
	
	
	









	
	
	
	
	











	
	
	
	
	










	
	
	
	
	









	
	
	
	
	











	
	
	
	
	











	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	









	
	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	
	













	
	
	
	













	
	
	
	
	













	
	
	
	
	











	
	
	
	
	











	
	
	
	
	













	
	
	
	
	
	











	
	
	
	
	
	











	
	
	
	
	
	









	
	
	
	
	











	
	
	
	
	











	
	
	
	
	
	









	
	
	
	
	











	
	
	
	
	











	
	
	
	











	
	
	
	
	









	
	
	
	
	









	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	
	









	
	
	
	









	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	











	
	
	
	









	
	
	
	
	









	
	
	
	
	











	
	
	
	
	











	
	
	
	
	




	
	
	
	
	





	
	
	
	
	











	
	











; and











wherein the therapeutically effective amount is about 10 to about 500 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.











10. Use of a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for treating cancer, wherein the medicament is for oral administration, and the compound is selected from:











	
	











	
	
	
	
	











	
	
	
	
	









	
	
	
	
	











	
	
	
	
	











	
	
	
	
	









	
	
	
	
	











	
	
	
	
	










	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	









	
	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	













	
	
	
	
	













	
	
	
	
	











	
	
	
	
	











	
	
	
	
	













	
	
	
	
	











	
	
	
	
	
	











	
	
	
	
	
	









	
	
	
	
	











	
	
	
	
	











	
	
	
	
	
	









	
	
	
	
	











	
	
	
	
	











	
	
	
	











	
	
	
	
	









	
	
	
	
	









	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	
	









	
	
	
	









	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	











	
	
	
	









	
	
	
	
	









	
	
	
	
	











	
	
	
	
	











	
	
	
	
	




	
	
	
	
	

; and

wherein the therapeutically effective amount is about 10 to about 500 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

11. The use of claim 10, wherein the cancer is selected from tumors of the central nervous system, breast cancer, prostate cancer, skin cancer (including basal cell carcinoma cell carcinoma, squamous cell carcinoma and melanoma), cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, glioma, pancreatic cancer, stomach cancer, liver cancer, colon cancer, renal cancer, bladder cancer, oesophageal cancer, cancer of the larynx, cancer of the parotid, cancer of the biliary tract, rectal cancer, endometrial cancer, adenocarcinomas, small cell carcinomas, neuroblastomas, mesotheliomas, adrenocortical carcinomas, epithelial carcinomas, desmoid tumors, desmoplastic small round cell tumors, endocrine tumors, Ewing sarcoma family tumors, germ cell tumors, hepatoblastomas, hepatocellular carcinomas, non-rhabdomyosarcoma, soft tissue sarcomas, osteosarcomas, peripheral primitive neuroectodermal tumors, retinoblastomas, rhabdomyosarcomas, and Wilms tumors.

12. The use of claim 10, wherein the cancer is a glioma.

13. The use of claim 12, wherein the glioma is diffuse intrinsic pontine glioma.

14. The use of any one of claims 5-13, wherein the therapeutically effective amount is about 10 to about 250 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

15. The use of any one of claims 5-14, wherein the medicament is to be administered once daily.

16. The use of any one of claims 5-15, wherein the medicament is to be administered for 1 day to 6 months.

17. The use of claim 16, wherein the medicament is to be administered for 7 days.

18. The use of claim 16, wherein the medicament is to be administered for 14 days.

19. The use of claim 16, wherein the medicament is to be administered for 21 days.

20. The use of claim 16, wherein the medicament is to be administered for 28 days.

21. The use of any one of claims 5-20, wherein the medicament is to be administered as a single oral dosage form.

22. The use of any one of claims 5-21, wherein the medicament is to be administered as a single hard or soft gelatin capsule.

23. The use of any one of claims 5-22, wherein the medicament is to be administered as an oral dosage form of any one of claims 1-4.

24. The oral dosage form of claim 1, for use in therapy.